Does Priority Health Cover Forteo? A Woman's Guide to Teriparatide Insurance Coverage

What Is Forteo and Why Do Women Need It?

Forteo is the brand name for teriparatide, a synthetic fragment of human parathyroid hormone (PTH 1-34) that works by stimulating new bone formation rather than simply slowing bone loss. That mechanism is what sets it apart from the bisphosphonates most women try first.

Teriparatide was studied in the landmark Fracture Prevention Trial published in the New England Journal of Medicine in 2001. In that trial of 1,637 postmenopausal women with prior vertebral fractures, teriparatide reduced new vertebral fracture risk by 65% and nonvertebral fracture risk by 53% compared to placebo over a median of 21 months. Those numbers reflect a genuinely anabolic drug, not just a bone-loss brake.

Who Gets Prescribed Forteo?

Women prescribed Forteo typically fall into one of these groups:

• Postmenopausal women with a T-score of <-2.5 plus one or more fragility fractures
• Women with a T-score of <-3.0 even without a fracture history
• Women who have lost bone or fractured on bisphosphonate therapy
• Women with glucocorticoid-induced osteoporosis at high fracture risk
• Perimenopausal women with severe secondary osteoporosis (for example, from long-term aromatase inhibitor use in breast cancer treatment)

The Endocrine Society's 2019 clinical practice guideline on osteoporosis in postmenopausal women recommends teriparatide as a first-line option specifically for women at very high fracture risk, not as a last resort.

The Female-Specific Physiology Behind the Prescription

Estrogen loss at menopause accelerates bone resorption dramatically. In the two to three years surrounding the final menstrual period, women can lose up to 10% of total bone mass, a rate far exceeding anything seen in age-matched men. Teriparatide's anabolic action is particularly well-matched to the postmenopausal skeleton because it recruits osteoblasts at a time when the resorption-formation balance is most disrupted.

Women on aromatase inhibitors for hormone-receptor-positive breast cancer face a compounding problem: estrogen suppression drives rapid bone loss on top of any pre-existing deficit. For this group, the pathway to Forteo may be shorter because bisphosphonates sometimes fail to fully offset AI-induced bone loss.

How Priority Health Formulary Coverage Works for Forteo

Priority Health is a Michigan-based health plan that covers members across commercial, Medicare Advantage, and Medicaid product lines. Coverage terms differ by plan type, so the first step is always to confirm which specific Priority Health product you carry.

Commercial Plans

On Priority Health commercial plans, Forteo is placed on a Tier 4 or Tier 5 specialty formulary tier. At Tier 5, your cost-sharing is typically a percentage of the drug's cost (coinsurance) rather than a flat copay, which can mean hundreds of dollars per month even after insurance pays its share.

Prior authorization is required. The standard clinical criteria Priority Health applies for Forteo align with criteria published by the FDA-approved Forteo prescribing information and major osteoporosis guidelines:

1. Documented diagnosis of osteoporosis (T-score of <-2.5 or fragility fracture history)
2. Trial and failure of, or contraindication to, at least one oral bisphosphonate (usually alendronate or risedronate for six to twelve months)
3. High fracture risk as established by FRAX score or clinical criteria
4. Prescriber documentation of why anabolic therapy is needed now

If you have never tried a bisphosphonate, expect Priority Health to require step therapy before approving Forteo unless your clinician documents a specific contraindication (for example, severe reflux esophagitis, very low creatinine clearance, or documented intolerance).

Medicare Advantage Plans Through Priority Health

If you carry a Priority Health Medicare Advantage plan, Forteo is covered under Part D rather than the medical benefit. The drug falls in the specialty tier, where standard cost-sharing is typically 25% to 33% coinsurance during the coverage gap. Medicare Part D specialty tier cost-sharing means your monthly out-of-pocket exposure can be substantial until you reach the catastrophic threshold.

The Inflation Reduction Act of 2022 capped Medicare Part D out-of-pocket drug spending at $2,000 per year starting in 2025, which meaningfully changes the math for women on Forteo under Medicare Advantage. If you are in a Medicare Advantage plan and facing a Forteo denial, the $2,000 annual cap makes appealing worth the effort.

Medicaid Plans Through Priority Health

Priority Health administers Medicaid managed care plans in Michigan. Medicaid formulary placement is governed by the Michigan Department of Health and Human Services. Teriparatide coverage under Medicaid plans is more restrictive and typically requires specialist documentation (endocrinologist or rheumatologist). Contact Priority Health member services directly at the number on your card to confirm current Medicaid formulary status before your clinician submits a prior authorization.

Walking Through the Prior Authorization Process

Getting Forteo approved takes preparation. Here is a practical sequence that has a higher likelihood of approval on the first submission.

Step 1: Confirm Your Bone Density Documentation

Your DEXA scan report is the foundation of the prior authorization. The report must show T-scores at the lumbar spine, total hip, and femoral neck. Make sure the scan was read by a radiologist or densitometrist and that the report includes the specific numeric T-scores, not just a narrative summary.

A DEXA performed within the past two years is usually acceptable. If your most recent scan is older, your clinician may need to order a new one before submitting the PA.

Step 2: Document the Step Therapy Requirement

Gather records showing you took a bisphosphonate for an adequate trial period (typically six to twelve months) and either:

• Lost bone or had a fracture while adherent, or
• Could not tolerate the drug due to documented side effects (for example, esophageal symptoms, atypical femur fracture concern, jaw osteonecrosis risk), or
• Have a medical contraindication (creatinine clearance below 35 mL/min makes bisphosphonates unsafe)

If your prescriber believes you need Forteo without prior bisphosphonate therapy because of very high fracture risk, the letter of medical necessity must explicitly invoke the Endocrine Society guideline or the American Association of Clinical Endocrinologists 2020 guidelines that support first-line anabolic therapy in patients at very high fracture risk.

Step 3: Your Clinician Submits the PA

The prescribing clinician submits the prior authorization through Priority Health's electronic PA portal or by fax. Priority Health is required by Michigan law and federal managed care regulations to respond to standard PA requests within three business days and urgent requests within 24 hours.

Step 4: Appeal If Denied

If Priority Health denies the PA, do not stop. Denial rates on specialty osteoporosis drugs are high on first submission, and published data show that more than 50% of oncology and specialty drug PA appeals are ultimately approved, a figure that applies broadly to specialty biologics. The appeal letter should:

• Quote the specific clinical criteria from the denial letter
• Reference the relevant guideline by name and publication date
• Include the FRAX score if not already submitted
• Include a signed letter of medical necessity from a specialist (endocrinologist, rheumatologist, or your OB-GYN if she manages your bone health)

You have the right to request an expedited external review if the denial creates an urgent medical situation.

The Real Cost of Forteo and How to Reduce It

The list price of Forteo in the United States is approximately $3,200 to $5,000 per month depending on the pharmacy and year. Few women pay that full price, but understanding your actual cost requires knowing three things: your plan's cost-sharing, your deductible status, and which assistance programs you qualify for.

Eli Lilly Forteo Savings Card

Eli Lilly offers a Forteo savings card for commercially insured patients. Eligible patients may pay as little as $4 per month for up to 24 months (the maximum treatment duration). This card cannot be used with Medicare or Medicaid. Confirm eligibility at the time of your first fill.

Lilly Cares Foundation Patient Assistance Program

If you are uninsured or underinsured and your income falls within qualifying thresholds, the Lilly Cares Foundation may provide Forteo at no cost. Applications require income documentation and prescriber participation.

Specialty Pharmacy Coordination

Priority Health typically requires Forteo to be dispensed through a contracted specialty pharmacy rather than a retail pharmacy. Ask your clinician's office which specialty pharmacies are in-network for your specific plan. Using an out-of-network specialty pharmacy may result in the claim being denied entirely.

Pregnancy, Lactation, and Contraception: Critical Safety Information for Women

Forteo is FDA Pregnancy Category X equivalent under the modern PLLR framework. That means animal studies showed fetal harm and there are no adequate human pregnancy data, and the potential risk outweighs any possible benefit.

Do not use teriparatide if you are pregnant or trying to conceive.

What the Animal Data Show

In rat studies, teriparatide caused skeletal abnormalities in offspring at doses that produced maternal blood levels similar to those seen in clinical use. The drug crosses the placental barrier in animal models. No controlled human pregnancy studies have been conducted, and given the mechanism of action on bone remodeling during fetal development, human use in pregnancy is not considered acceptable.

Lactation

It is not known whether teriparatide passes into human breast milk. The FDA prescribing information states that because of the potential for serious adverse reactions in nursing infants, women should not breastfeed while taking Forteo.

Women who have recently delivered and are postpartum but not breastfeeding should discuss with their clinician whether the timing of Forteo initiation is appropriate.

Contraception Requirement

Women of reproductive potential taking Forteo should use effective contraception throughout the treatment course. If you are perimenopausal and have not had 12 consecutive months of amenorrhea, you should not assume you are infertile.

Effective options include combined hormonal contraceptives, progestin-only methods, or a levonorgestrel IUD. The levonorgestrel IUD has the added benefit of minimizing uterine bleeding in perimenopausal women and may be particularly practical for this group.

Life Stage Specifics

• Reproductive years: Teriparatide is rarely indicated at this life stage. Osteoporosis in premenopausal women is uncommon and usually secondary (amenorrhea, eating disorders, glucocorticoid use). If Forteo is genuinely needed in a premenopausal woman, pregnancy prevention is non-negotiable.
• Perimenopause: Bone loss accelerates in this transition. Women with very high fracture risk entering perimenopause may be candidates, but must use contraception until menopause is confirmed.
• Postmenopause: This is the primary population. No contraception concerns apply, but the maximum 24-month treatment limit still applies.

Who This Drug Is Right For and Who It Is Not

This framework is based on the Endocrine Society 2019 guideline and clinical criteria that Priority Health mirrors in its PA criteria.

Likely a Good Candidate

• Postmenopausal woman with T-score of <-2.5 and one or more vertebral or hip fractures
• Postmenopausal woman with T-score of <-3.0 regardless of fracture history
• Woman who fractured a hip or vertebra while on adequate bisphosphonate therapy
• Woman with severe glucocorticoid-induced osteoporosis (prednisone 5 mg/day or more for three or more months)
• Perimenopausal woman on aromatase inhibitor therapy with rapidly declining bone density and documented fracture risk

Probably Not the Right Starting Point

• Woman with newly diagnosed osteoporosis and no prior fractures who has not tried a bisphosphonate
• Woman with osteopenia (T-score between -1.0 and -2.5) and low FRAX score
• Woman with a history of bone metastases, hypercalcemia, or prior skeletal radiation (these are contraindications per the FDA prescribing label)
• Woman with Paget's disease of bone or unexplained elevated alkaline phosphatase
• Pregnant or breastfeeding women (absolute contraindication)

After Forteo: Sequential Therapy Matters

Teriparatide builds new bone over 24 months. The DATA study (Denosumab and Teriparatide Administration) and subsequent research show that the bone gained during teriparatide therapy is lost rapidly if no antiresorptive agent follows. The ACOG Committee Opinion on osteoporosis and Endocrine Society guidelines both recommend transitioning to an antiresorptive drug (typically denosumab or a bisphosphonate) immediately after completing the Forteo course.

Make sure your Priority Health coverage for the follow-on medication is confirmed before you complete your 24-month teriparatide course.

Evidence Gap: What We Do Not Know

Women have been the majority of osteoporosis trial participants, so the data for teriparatide in postmenopausal women are relatively strong compared to many other drug categories. The Fracture Prevention Trial enrolled only women. That is a strength for this specific population.

Where data are thinner:

• Premenopausal women: Evidence is extrapolated from case series and small trials, not large RCTs.
• Women on aromatase inhibitors: The bone density benefits of teriparatide in this group are supported by small trials, not the large fracture-endpoint trials.
• Racial and ethnic diversity: The key trial enrolled predominantly white women. Fracture risk calculators and T-score thresholds may perform differently across racial groups, a limitation that affects prescribing decisions for all women of color but is rarely discussed in coverage criteria.

Be explicit with your clinician if you want to understand whether the evidence for your specific situation is from direct study or extrapolation.

Practical Next Steps

If you are on a Priority Health plan and your clinician has recommended Forteo, here is what to do this week.

1. Call the member services number on the back of your Priority Health card and ask specifically: "Is teriparatide (brand name Forteo) covered on my plan, and what are the prior authorization criteria?"
2. Ask your clinician's office to pull your most recent DEXA report and confirm it is less than two years old.
3. If you have prior bisphosphonate prescriptions, ask the pharmacy to print a medication history showing the drug, start date, and duration.
4. Ask your clinician about your FRAX score. A FRAX score showing a ten-year major osteoporotic fracture risk of 20% or greater is a strong component of any letter of medical necessity.
5. If you are commercially insured (not Medicare or Medicaid), contact Eli Lilly at 1-800-545-5979 to register for the Forteo savings card before your first fill.

A 2023 analysis in the Journal of Managed Care and Specialty Pharmacy found that prior authorization delays for osteoporosis anabolic agents average 23 days from submission to approval, meaning you should start this process at least three to four weeks before you plan to begin injections.